Related Experiment Videos
Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy
H Yokoyama1, B Myrup, P Rossing
1Steno Diabetes Center, Novo Nordisk a@s, Gentofte, Denmark.
Diabetes Care
|May 1, 1996
Summary
Plasma tissue factor pathway inhibitor (TFPI) activity is elevated in type 1 diabetes with nephropathy, linked to LDL cholesterol and glycemic control. This increased TFPI may partially offset hypercoagulability but doesn't normalize hemostasis.
Area of Science:
- Biochemistry
- Endocrinology
- Vascular Biology
Background:
- Tissue factor pathway inhibitor (TFPI) is a key regulator of the extrinsic coagulation pathway.
- TFPI circulates in plasma, often bound to lipoproteins, and inhibits factor Xa.
- Alterations in TFPI may play a role in the thrombotic complications associated with diabetes.
Purpose of the Study:
- To investigate plasma TFPI activity in patients with type 1 diabetes (IDDM) and varying degrees of nephropathy.
- To identify potential determinants, such as lipoproteins and metabolic control, of altered TFPI activity in diabetes.
Main Methods:
- Plasma concentrations of total, truncated, and domain 3 TFPI were measured.
- Factor Xa inhibition activity was assessed using the HEPTEST assay.
- Levels were compared between non-diabetic controls and IDDM patients with normoalbuminuria, incipient nephropathy, and clinical nephropathy.
Main Results:
- TFPI concentrations and factor Xa inhibition activity were significantly increased in IDDM patients, particularly those with nephropathy.
- Increased TFPI activity was correlated with higher LDL cholesterol and HbA1c levels.
- Despite elevated TFPI, markers of thrombin generation (prothrombin fragment 1 + 2) remained high, indicating insufficient anticoagulant effect.
Conclusions:
- Plasma TFPI activity and its inhibitory function are elevated in IDDM patients with nephropathy.
- Increased TFPI levels appear to be associated with dyslipidemia (LDL cholesterol) and poor glycemic control (HbA1c).
- While TFPI may offer some protection against the hypercoagulable state in diabetes, it does not fully restore normal hemostasis.